Hemophilia B Gene Therapy Market PRIMEd In Europe

UniQure’s gene therapy, AMT-060, has been accepted into the European Medicines Agency’s priority medicines scheme, PRIME, a move likely to intensify the race to market of a small group of gene therapies for hemophilia B, all currently in Phase I/II studies.